IMMUNITYBIO, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
IMMUNITYBIO, INC. (IBRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of -$240.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2023-05-11
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was -$240.00K.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$111.00K.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$223.00K.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$247.00K.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2022 was -$753.00K.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2021 was -$3.06M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2020 was -$2.34M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2019 was -$2.38M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$240.00K 10-Q · filed 2023-05-11 | -$351.00K derived: sum of 2 quarters · filed 2023-05-11 | -$574.00K derived: sum of 3 quarters · filed 2023-05-11 | -$821.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$334.00K derived: sum of 2 quarters · filed 2023-03-01 | -$581.00K derived: sum of 3 quarters · filed 2023-03-01 | -$753.00K 10-K · filed 2023-03-01 |
| 2022-09-30 | -$223.00K 10-Q · filed 2022-11-09 | -$470.00K derived: sum of 2 quarters · filed 2022-11-09 | -$642.00K 10-Q · filed 2022-11-09 | -$936.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | -$247.00K 10-Q · filed 2022-08-08 | -$419.00K 10-Q · filed 2022-08-08 | -$713.00K derived: sum of 3 quarters · filed 2023-05-11 | -$1.51M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | -$172.00K 10-Q · filed 2023-05-11 | -$466.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.27M derived: sum of 3 quarters · filed 2023-05-11 | -$2.36M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$1.09M derived: sum of 2 quarters · filed 2023-03-01 | -$2.19M derived: sum of 3 quarters · filed 2023-03-01 | -$3.06M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$800.00K 10-Q · filed 2022-11-09 | -$1.90M derived: sum of 2 quarters · filed 2022-11-09 | -$2.76M 10-Q · filed 2022-11-09 | -$3.57M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$1.10M 10-Q · filed 2022-08-08 | -$1.96M 10-Q · filed 2022-08-08 | -$2.77M derived: sum of 3 quarters · filed 2023-03-01 | -$3.33M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$867.00K 10-Q · filed 2022-05-10 | -$1.67M derived: sum of 2 quarters · filed 2023-03-01 | -$2.24M derived: sum of 3 quarters · filed 2023-03-01 | -$2.81M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$1.37M derived: sum of 2 quarters · filed 2023-03-01 | -$1.95M derived: sum of 3 quarters · filed 2023-03-01 | -$2.34M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$567.00K 10-Q · filed 2021-11-12 | -$1.15M derived: sum of 2 quarters · filed 2021-11-12 | -$1.53M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$578.00K 10-Q · filed 2021-08-12 | -$967.00K 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | -$2.38M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |